[Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] A problem with creating a new vacc is difficult to study/show that it is superior to current vaccine. Though 7milliin cases yearly, measles is not common among people participating in efficacy trials. So getting efficacy and proving superiority/durability would be very tough.